Where does CTOR stock trade?

Citius Oncology Inc. (CTOR) is listed on NASDAQ.

What sector and industry is CTOR in?

Citius Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Citius Oncology Inc. go public?

Citius Oncology Inc. (CTOR) completed its IPO in 2022.

What are analysts saying about CTOR?

Citius Oncology Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2025-09-23. Recent price targets range from $300.00 to $600.00.

What companies are similar to CTOR?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CTOR side-by-side with any of them on Quantisnow.

How can I track CTOR on Quantisnow?

Quantisnow aggregates Citius Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTOR to receive live email and push alerts on every new disclosure.

CTOR

NASDAQ

Citius Oncology Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2022

$0.68-0.06 (-7.69%)

News25/Ratings2

Price$0.68-0.32 (-32.31%)

2026-03-092026-06-10

News · 26 weeks55-9%

2025-12-142026-06-07

Mix2390d

SEC Filings13(57%)
Other9(39%)
Offering1(4%)

Latest news

25 items

3dSEC
SEC Form EFFECT filed by Citius Oncology Inc.
EFFECT - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
6dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Citius Oncology Inc.
SCHEDULE 13D/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
9dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
9dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
10dPR
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-treated patients20.5 months of median progression-free survival observed among 48% of efficacy-evaluable patients achieving clinical benefit (10 of 21) Responses were observed in patients previously treated with immune checkpoint inhibitors, including a 33% objective response rate in patients with relapsed or refractory endometrial cancerCRANFORD, N.J., June 1, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑
12dSEC
SEC Form DEF 14C filed by Citius Oncology Inc.
DEF 14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
12dSEC
SEC Form S-3 filed by Citius Oncology Inc.
S-3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
16dPR
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Investigator-initiated study of LYMPHIR in combination with pembrolizumab to be presented during immunotherapy session, highlighting potential role of LYMPHIR beyond CTCLCRANFORD, N.J., May 26, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated
19dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
22dSEC
SEC Form PRE 14C filed by Citius Oncology Inc.
PRE 14C - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
26dSEC
Citius Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
26dSEC
SEC Form 10-Q filed by Citius Oncology Inc.
10-Q - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
26dPR
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR® launch progressesUp to $36.5 million in debt and equity capital securedBroad payer coverage established with no reimbursement denials83% of target accounts on formulary or in reviewCRANFORD, N.J., May 15, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today reported financial results for the fiscal second quarter ended March 31, 2026, and provided a business update.
26dPR
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 million in debt and equity financingAdvanced patient access with payer coverage near 100% of commercial lives and 83% of LYMPHIR target accounts on formulary or in review CRANFORD, N.J., May 15, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today reported business and financial results for the fiscal second quarter ended March 31
26dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Citius Oncology Inc.
SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
35dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
35dSEC
Citius Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
36dSEC
SEC Form 424B3 filed by Citius Oncology Inc.
424B3 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
42dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
43dPR
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launchDistribution by regional partners through Named Patient Programs in specific international marketsCRANFORD, N.J., April 29, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced the initial shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe through one of its regional distribution partners, marking an important milestone in expanding access to the therapy for patients outside the United States. LYMPHIR will be made
43dSEC
Citius Oncology Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
71dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
79dPR
Citius Oncology to Participate in USCLC Annual Workshop 2026, Highlighting LYMPHIR™ in Discussions with Leading Cutaneous Lymphoma Experts
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings availableCRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced that members of its commercial and medical affairs teams will attend the USCLC Annual Workshop 2026. The meeting, titled "Frontiers in Cutaneous Lymphoma: New Technologies, Therapeutics, and Future Directions," will take place on March 26, 2026, at the Hyatt Regency Denver at Colorado Convention
92dSEC
Citius Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
92dPR
Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase 1 Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacyTopline data of University of Pittsburgh-led trial to be presented at an upcoming international cancer conference later this yearCRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced positive topline results from a completed investigator‑initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators. This study evalu

CTOR FAQ

6 questions

Where does CTOR stock trade?
Citius Oncology Inc. (CTOR) is listed on NASDAQ.
What sector and industry is CTOR in?
Citius Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Citius Oncology Inc. go public?
Citius Oncology Inc. (CTOR) completed its IPO in 2022.
What are analysts saying about CTOR?
Citius Oncology Inc. has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2025-09-23. Recent price targets range from $300.00 to $600.00.
What companies are similar to CTOR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CTOR side-by-side with any of them on Quantisnow.
How can I track CTOR on Quantisnow?
Quantisnow aggregates Citius Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTOR to receive live email and push alerts on every new disclosure.